Gene Narcotic Attenuation Program attenuates substance use disorder, a clinical subtype of reward deficiency syndrome

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Advances in Therapy

• Publication date

  2007-03-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1007/BF02849910PMID 17565932
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Genotrim, a DNA-customized nutrigenomic product, targets genetic factors of obesity: hypothesizing a dopamine-glucose correlation demonstrating reward deficiency syndrome (RDS).

  2007cited by this paper
• Synaptamine (SG8839),TM An Amino-Acid Enkephalinase Inhibition Nutraceutical Improves Recovery of Alcoholics, A Subtype of Reward Deficiency Syndrome (RDS)

  2007cited by this paper
• Manipulation of catechol-O-methyl-transferase (COMT) activity to influence the attenuation of substance seeking behavior, a subtype of Reward Deficiency Syndrome (RDS), is dependent upon gene polymorphisms: a hypothesis.

  2007cited by this paper
• A theoretical argument for inherited thiamine insensitivity as one possible biological cause of familial alcoholism.

  2006cited by this paper
• Adenylyl cyclase type 5 (AC5) is an essential mediator of morphine action.

  2006cited by this paper
• High levels of dopamine D2 receptors in unaffected members of alcoholic families: possible protective factors.

  2006cited by this paper
• DNA based customized nutraceutical "gene therapy" utilizing a genoscore: a hypothesized paradigm shift of a novel approach to the diagnosis, stratification, prognosis and treatment of inflammatory processes in the human.

  2006cited by this paper
• Bariatric Surgery Cannot Prevent Tryptophan Depletion Due to Chronic Immune Activation in Morbidly Obese Patients

  2006cited by this paper
• β-Endorphin-induced locomotor stimulation and reinforcement are associated with an increase in dopamine release in the nucleus accumbens

  2005cited by this paper
• Relationship between dopaminergic neurotransmission, alcoholism, and reward deficiency syndrome

  2005cited by this paper
• [Hypothesis: Parkinson's disease, reward deficiency syndrome and addictive effects of levodopa].

  2004cited by this paper
• DREAM ablation selectively alters THC place aversion and analgesia but leaves intact the motivational and analgesic effects of morphine

  2004cited by this paper
• Acute and chronic ethanol treatment changes endorphin levels in brain and pituitary

  2004cited by this paper
• Reduction of withdrawal signs after chronic nicotine exposure of alpha-calcitonin gene-related peptide knock-out mice.

  2004cited by this paper
• Prevalence and Co-Occurrence of Substance Use Disorders and Independent Mood and Anxiety Disorders

  2004cited by this paper
• The A1 allele of the DRD2 gene (TaqI A polymorphisms) is associated with antisocial personality in a sample of alcohol-dependent patients

  2003cited by this paper
• Decreased ethanol preference and wheel running in Nurr1‐deficient mice

  2003cited by this paper
• Perspectives on Reward Circuitry, Neurobiology, Genetics and Pathology: Dopamine and Addiction

  2001cited by this paper
• Reward deficiency syndrome: genetic aspects of behavioral disorders.

  2000cited by this paper
• A national evaluation of treatment outcomes for cocaine dependence.

  1999cited by this paper
• Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine?

  1999cited by this paper
• A functionally deficient DRD2 variant [Ser311Cys] is not linked to alcoholism and substance abuse.

  1998cited by this paper
• Disruption of the κ‐opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective κ‐agonist U‐50,488H and attenuates morphine withdrawal

  1998cited by this paper
• Linkage and association of a functional DRD2 variant [Ser311Cys] and DRD2 markers to alcoholism, substance abuse and schizophrenia in Southwestern American Indians.

  1997cited by this paper
• Enhancement of Attention Processing by Kantroll™ in Healthy Humans: A Pilot Study

  1997cited by this paper
• The D2 Dopamine Receptor Gene as a Determinant of Reward Deficiency Syndrome

  1996cited by this paper
• REWARD DEFICIENCY SYNDROME

  1996cited by this paper
• NeuRecover-SA™ in the Treatment of Cocaine Withdrawal and Craving

  1996cited by this paper
• Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behaviour.

  1995cited by this paper
• Substance Abuse: A Comprehensive Textbook

  1992cited by this paper
• Allelic association of human dopamine D2 receptor gene in alcoholism.

  1990cited by this paper
• Neurodynamics of relapse prevention: a neuronutrient approach to outpatient DUI offenders.

  1990cited by this paper
• Improvement of inpatient treatment of the alcoholic as a function of neurotransmitter restoration: a pilot study.

  1988cited by this paper
• Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats.

  1988cited by this paper
• Enkephalinase inhibition and precursor amino acid loading improves inpatient treatment of alcohol and polydrug abusers: double-blind placebo-controlled study of the nutritional adjunct SAAVE.

  1988cited by this paper
• Reduction of both drug hunger and withdrawal against advice rate of cocaine abusers in a 30-day inpatient treatment program by the neuronutrient tropamine

  1988cited by this paper
• Enkephalinase inhibition: regulation of ethanol intake in genetically predisposed mice.

  1987cited by this paper
• Effects of Chronic Ethanol Treatment on the In Vitro Biosynthesis of Pro‐Opiomelanocortin and ItsPosttranslational Processing to (β‐Endorphin in theIntermediate Lobe of the Rat Pituitary

  1984cited by this paper
• Reduced leucine-enkephalin--like immunoreactive substance in hamster basal ganglia after long-term ethanol exposure.

  1982cited by this paper
• Long‐Term Treatment of Rats with Morphine Reduces the Activity of Messenger Ribonucleic Acid Coding for the β‐Endorphin/ACTH Precursor in the Intermediate Pituitary

  1982cited by this paper

• Neurospirituality Connectome - Role in Neurology and Reward Deficiency Syndrome (RDS).

  2025cites this paper
• Multi-Locus Pro-Dopaminergic Restoration of Reward Brain Circuitry in Reward Deficiency Rescinds Mono-Pharmaceutical Targeting.

  2025cites this paper
• Is There a Natural, Non-addictive, and Non-anti-reward, Safe, Gene-based Solution to Treat Reward Deficiency Syndrome? KB220 Variants vs GLP-1 Analogs

  2024influential citation
• Summary Document Research on RDS Anti-addiction Modeling: Annotated Bibliography

  2024cites this paper
• Invited Expert Opinion- Bioinformatic and Limitation Directives to Help Adopt Genetic Addiction Risk Screening and Identify Preaddictive Reward Dysregulation: Required Analytic Evidence to Induce Dopamine Homeostatsis

  2023cites this paper
• Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids

  2022cites this paper
• Precision Behavioral Management (PBM) and Cognitive Control as a Potential Therapeutic and Prophylactic Modality for Reward Deficiency Syndrome (RDS): Is There Enough Evidence?

  2022cites this paper
• Cannabis-Induced Hypodopaminergic Anhedonia and Cognitive Decline in Humans: Embracing Putative Induction of Dopamine Homeostasis

  2021cites this paper
• The Role of Nutrition in Addiction Recovery

  2019cites this paper
• Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated)

  2018cites this paper
• Genetic addiction risk score (GARS) ™, a predictor of vulnerability to opioid dependence.

  2018influential citation
• Pro-dopamine regulator, KB220Z, attenuates hoarding and shopping behavior in a female, diagnosed with SUD and ADHD

  2018cites this paper
• Pro-Dopamine Regulator-( KB 220 ) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome ( RDS ) Mini-review

  2017cites this paper
• Hypothesizing That Neuropharmacological and Neuroimaging Studies of Glutaminergic-Dopaminergic Optimization Complex (KB220Z) Are Associated With “Dopamine Homeostasis” in Reward Deficiency Syndrome (RDS)

  2017cites this paper
• Pro-Dopamine Regulator – (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome (RDS)

  2017cites this paper
• Coupling Genetic Addiction Risk Score (GARS) and Pro Dopamine Regulation (KB220) to Combat Substance Use Disorder (SUD).

  2017cites this paper
• KB220Z™ a Pro-Dopamine Regulator Associated with the Protracted, Alleviation of Terrifying Lucid Dreams. Can We Infer Neuroplasticity-induced Changes in the Reward Circuit?

  2016cites this paper
• Hypothesizing that a Pro-Dopaminergic Regulator (KB220z™ Liquid Variant) can Induce “Dopamine Homeostasis” and Provide Adjunctive Detoxification Benefits in Opiate/Opioid Dependence

  2016cites this paper
• Neuronutrient Amino-Acid Therapy Protects Against Reward Deficiency Syndrome: Dopaminergic Key to Homeostasis and Neuroplasticity.

  2016cites this paper
• “Pro-dopamine regulation (KB220Z™)” as a long-term therapeutic modality to overcome reduced resting state dopamine tone in opiate/opioid epidemic in America

  2016cites this paper
• Low Dopamine Function in Attention Deficit/Hyperactivity Disorder: Should Genotyping Signify Early Diagnosis in Children?

  2014cites this paper
• Neurogenetics and nutrigenomics of reward deficiency syndrome (RDS): Stratification of addiction risk and mesolimbic nutrigenomic manipulation of hypodopaminergic function

  2013cites this paper
• Iatrogenic opioid dependence is endemic and legal: Genetic addiction risk score (GARS) with electrotherapy a paradigm shift in pain treatment programs

  2013cites this paper
• Neurogenetics and Nutrigenomics of Neuro-Nutrient Therapy for Reward Deficiency Syndrome (RDS): Clinical Ramifications as a Function of Molecular Neurobiological Mechanisms.

  2012cites this paper
• Menagerie of Chromium Supplements

  2012cites this paper
• Kenneth Blum 1,5,6,8,10,11,12,15*, Marlene Oscar-Berman2, Elizabeth Stuller3, David Miller4,5, John Giordano6, Siobhan Morse6, Lee McCormick7, William Downs B5, Roger L Waite5, Debmalya Barh8, Dennis Neal9, Eric R Braverman1,10, Raquel Lohmann10, Joan Borsten11, Mary Hauser12, David Han13, Yijun Liu

  2012cites this paper
• Neuro-chemical activation of brain reward meso-limbic circuitry is associated with relapse prevention and drug hunger: a hypothesis.

  2011cites this paper
• Nutrigenomics of Neuradaptogen Amino-Acid-Therapy and Neurometabolic Optimizers: Overcoming carbohydrate bingeing and overeating through neurometabolic mechanisms

  2011cites this paper
• Hypothesizing Synergy between Acupuncture/ Auriculotherapy and Natural Activation of Mesolimbic Dopaminergic Pathways: Putative Natural Treatment Modalities for the Reduction of Drug Hunger and Relapse

  2011cites this paper
• Effect of Dopamine Receptor DRD2 and ANKK1 Polymorphisms on Dietary Compliance, Blood Pressure, and BMI in Type 2 Diabetic Patients

  2010cites this paper
• Hypothesizing that brain reward circuitry genes are genetic antecedents of pain sensitivity and critical diagnostic and pharmacogenomic treatment targets for chronic pain conditions.

  2009cites this paper
• Putative targeting of Dopamine D2 receptor function in Reward Deficiency Syndrome (RDS) by Synaptamine Complex™ Variant (KB220): Clinical trial showing anti-anxiety effects

  2009influential citation
• Neurogenetics of Dopaminergic Receptor Supersensitivity in Activation of Brain Reward Circuitry and Relapse: Proposing “Deprivation-Amplification Relapse Therapy” (DART)

  2009cites this paper
• Dopamine D2 receptor Taq A1 allele predicts treatment compliance of LG839 in a subset analysis of pilot study in the Netherlands

  2008cites this paper
• Mesolimbic Reward Circuitry and Reward Deficiency Syndrome (RDS): A Commentary on Long Term Dopaminergic Therapy

  2008cites this paper
• Theoretical Biology and Medical Modelling Activation Instead of Blocking Mesolimbic Dopaminergic Reward Circuitry Is a Preferred Modality in the Long Term Treatment of Reward Deficiency Syndrome (rds): a Commentary

  year unknowncites this paper